CD274 and neoplasm: For patients without oncogenic driver mutations, treatment options can be considered based on PD-L1 status [11]; immunotherapy as a monotherapy can be used for patients with tumour PD-L1 ≥ 50% and immunotherapies can be used in combination with chemotherapy in patients irrespective of PD-L1 status but mostly preferred for those with PD-L1 < 50%.